2021
Authors: Cressey RT, Abbassi M, Lallemant M, Indolfi G, Al-Nahari M, Farid S, Easterbrook P, Penazzato M, El-Sayed HM
Published in: CROI 2021
Abstract: World Health Organization 2018 guidelines recommend Sofosbuvir (SOF)/Daclatasvir (DCV) as a pangenotypic regimen for the treatment of adults with chronic HCV infection. SOF/DAC is widely available as low-cost generic formulation in low and middle-income countries (LMICs).
2020
Author: Bilardi D, Rapa E, Bernays S, & Lang T
Published in: European Academy of Pediatric Societies
Background: Despite health research capacity development (HRCD) in low and middle-income countries (LMICs) being recognised as a critical element to overcoming global health challenges, insufficient actions have been taken to tackle major barriers to HRCD.
2020
Author: Mark A. Turner, Katharine Cheng, Saskia de Wildt, Heidrun Hildebrand, Sabah Attar, Paolo Rossi, Donato Bonifazi, Adriana Ceci, Joana Claverol, Begonya Nafria, Carlo Giaquinto
Published in: British Journal of Clinical Pharmacology
Abstract: Paediatric drug development faces several barriers. These include fragmentation of stakeholders and inconsistent processes during the conduct of research. This review summarises recent efforts to overcome these barriers in Europe.
2020
Authors: Vasconcelos MK, Epalza C, Renk H, Tagarro A, Bielicki JA
Published in: Lancet Infect Dis. 2020;24
In their Comment, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) clinical characterisation group outline how harmonisation of clinical characterisation studies is achieved through their collaborative resource-sharing and data-sharing platform. We fully agree with both the importance of international harmonisation and the authors’
2020
Authors: V. Matheeussen, K. Loens, K. Jacobs, P. Horby, H. Goossens, M. Kohns Vasconcelos, M. Sharland, M. De Jong, M. P. G. Koopmans, P. Fraaij, M. Ieven
Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020
Background: The management of infants admitted to hospital with sepsis-like syndrome (SLS) without apparent focus remains challenging.
2020
Authors: M. Kohns Vasconcelos; on behalf of the PED-MERMAIDS Study Group
Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020
Background: Recently, major aetiology and outcome studies on paediatric acute respiratory tract infections (ARI) have been reported from LMICs. In contrast, studies using standardised protocols across Europe are lacking.
2019
Authors: Kaguelidou F, Le Roux E, Mangiarini L, et al.; GAPP consortium
Published in: BMJ Open. 2019;9(2):e023296
Introduction Gabapentin is currently used ‘off-label’ in children and adolescents with chronic neuropathic pain, and reliable evidence of its effects and optimal dosing are lacking.
Objectives The GABA-1 trial aims to compare the efficacy and safety of gabapentin liquid formulation relative to tramadol and to explore the pharmacokinetics of both drugs in the treatment of chronic,
2019
Authors: de Leeuw TG, Mangiarini L, Lundin R, et al; GAPP consortium
Published in: Trials. 2019; 20(1):368
Background Gabapentin has shown efficacy in the treatment of chronic neuropathic or mixed pain in adults. Although pediatric pain specialists have extensive experience with gabapentin for the treatment of neuropathic pain, its use is off-label. Its efficacy and safety in this context have never been shown.